"-...mommy, daddy I wanna be a doctor. I wanna save others' lives! - Oh, great, We proud u, darling". These dialogues are not rare for families from different countries. In fact, there are such types of jobs which are respected in every society and several-ones are linked to the healthcare industry. I don't think that within this article you would like to read about cultural misunderstandings in the healthcare ethics. According to the 2014 Global Health Care Outlook by Deloitte, we have to accept that the industry importance will continue to grow cause of an aging population and people with chronic diseases increase. Chart 1. 2014 Global Healthcare industry outlook This chart proves the view, that healthcare industry will grow according to the demographics and health care spending increase in emerging markets. Therefore we decided to look throw the industry and we found a suitable stock. So, let us present American biotechnology company Gilead Sciences. Chart 2. Gilead Worldwide Operations Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need. Gilead was founded in 1987 in Foster City, California. Since then, Gilead has become one of the largest biopharmaceutical companies in the world, with a rapidly expanding product portfolio and a growing pipeline of investigational drugs. Chart 3. Gilead Operational Performances Gilead's portfolio of products and pipeline of investigational drugs includes treatments for HIV/AIDS, liver diseases, cancer, inflammatory and respiratory diseases, and cardiovascular conditions. It should be pointed out that company's pill which cures hepatitis C has boosted total products sales and profit and this invention continues affecting on financial results. So, the total product sales increased form $5.968 billion in Q3 2014 to $ 8.211 billion in Q3 2015 ( + 27%). Also there are minor changes in operating cash flows estimated about $4.044 billion - $ 4.097 billion in the same periods. Chart 4. Gilead Profitability Ratio According to this chart, all profitability ratios show a sustainable growth for the last 3 years, especially return on costs which is 129.7% higher than in 2013. Also return on sales and equity have a positive trend and both estimate 68.7% and 74.8% respectively in 2015. There are several reasons for these features. Moreover, Gilead reducing its production costs and increasing assets turnover and these measures lead to significant profit growth. That is why the company has an effective current and fixed assets management. Table 1. Gilead Economic Development (SG) This table presents an economic development ratio (SG) of Gilead for the last twp years. In 2015 it was 0.3 higher than in 2014 and estimated 1.56. This growth was linked to own capital increase and positive return on net assets coupled with retained earnings rally. Finally all these figures underline right way of strategic development, effective logistics and production. Chart 5. Gilead Daily Chart. $GILD, Gilead Sciences, Inc. / 1440 July 24, 2015 - It's a all time highest price of the stock estimated $123.37. In fact, Gilead shows a significant growth for the last 2 years and 3 times stock price increase for the last 3 years. As it was previously mentioned, the company launched new types of drugs for HIV treatment in 2014. By the way, there are other brands in Gilead's portfolio, such as successful Harvoni and Sovaldi against hepatitis C, cardiovascular Letaris and Ranexa, which total sales exceeded $1 billion in 2014 and Zydelig, a new medicine for chronic lymphoid malignancy. All these drugs are quite expensive and useful, approximately $1000 per one tablet but Gilead continues cutting costs around the world. Partnership contracts with Georgia and Egypt about hepatitis drugs towered to the strategic position on this market.